当前位置：药药网 / 数据中心 / 临床注释-2,变异和临床注释数据
伏立康唑
临床注释ID
1183689217
药物名称(英)
voriconazole
变异单倍型
CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17
基因
CYP2C19
证据级别
1A
水平覆盖
水平修饰符
Tier 1 VIP
表现型类别(英)
Metabolism/PK
表现型类别
代谢/PK
分数
268.5625
PMID计数
47
计数的证据
77
表现型
表现型(英)
最新日期
2021/4/26 0:00:00
URL
https://www.pharmgkb.org/clinicalAnnotation/1183689217
专业人口(英)
Pediatric
专业人口
儿科
临床等位基因
id等位基因注释文本
596 *17 The CYP2C19*17 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C19*17 allele in combination with a normal or increased function allele may have increased metabolism of voriconazole as compared to patients with two normal function alleles. Patients carrying the CYP2C19*17 allele in combination with a no or decreased function allele may have decreased metabolism of voriconazole as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and voriconazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of voriconazole.
595 *3 The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of voriconazole as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and voriconazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of voriconazole.
594 *2 The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of voriconazole as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and voriconazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of voriconazole.
593 *1 The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have increased metabolism of voriconazole as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have decreased metabolism of voriconazole as compared to patients with a normal function allele in combination with an increased function allele or two increased function alleles. However, conflicting evidence has been reported. However some studies showed no association. This annotation only covers the pharmacokinetic relationship between CYP2C19 and voriconazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of voriconazole.
临床证据
id证据的ID总结
4005 1448525969 CYP2C19 *1/*1 is associated with decreased trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3.
4004 1448123818 CYP2C19 *1/*2 + *1/*3 + *2/*2 + *3/*3 are not associated with trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.
4003 1448123702 CYP2C19 *1/*2 is not associated with clearance of voriconazole in people with hematopoietic stem cell transplantation as compared to CYP2C19 *1/*1.
4002 1448112553 CYP2C19 *1/*1 is associated with increased clearance of voriconazole in healthy individuals as compared to CYP2C19 *1/*2 + *2/*2.
4001 1447962788 CYP2C19 *17/*17 is associated with decreased concentrations of voriconazole in infants with Severe Combined Immunodeficiency.
4000 1447944162 CYP2C19 *1/*2 + *1/*3 (assigned as intermediate metabolizers phenotype) are not associated with trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .
3999 1447944149 CYP2C19 *2/*2 + *2/*3 (assigned as poor metabolizers phenotype) are associated with increased trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .
3998 1447944137 CYP2C19 *1/*1 is associated with decreased trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *1/*3 + *2/*3.
3997 1447944033 CYP2C19 *1/*1 is not associated with trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *1/*2 + *1/*3 + *2/*3 + *2/*2.
3996 1447681119 CYP2C19 *1/*17 + *17/*17 is associated with increased metabolism of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.
3995 1447681077 CYP2C19 *1/*2 is associated with decreased metabolism of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.
3994 1447681039 CYP2C19 *1/*2 + *2/*2 is not associated with dose-adjusted trough concentrations of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.
3993 1447681020 CYP2C19 *1/*17 + *17/*17 is associated with decreased dose-adjusted trough concentrations of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.
3992 1447680776 CYP2C19 *1/*2 + *2/*2 is associated with increased trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.
3991 1447680755 CYP2C19 *1/*17 + *17/*17 is associated with decreased trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.
3990 1447672698 CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with increased concentrations of voriconazole in healthy individuals as compared to CYP2C19 *1/*1.
3989 1447672688 CYP2C19 *1/*2 + *1/*3 is associated with increased concentrations of voriconazole in healthy individuals as compared to CYP2C19 *1/*1.
3988 1446897275 CYP2C19 *1/*2 + *1/*3 (assigned as intermediate metabolizers phenotype) are associated with decreased trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *2/*2 + *2/*3 (assigned as poor metabolizer phenotype) .
3987 1445584831 CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 is associated with increased concentrations of voriconazole in children as compared to CYP2C19 *1/*1 + *1/*17 (assigned as normal metabolizer phenotype) .
3986 1445556737 CYP2C19 *1/*17 (assigned as ultrarapid metabolizer phenotype) is associated with decreased concentrations of voriconazole as compared to CYP2C19 *1/*1.
3985 1445556721 CYP2C19 *1/*17 (assigned as ultrarapid metabolizer phenotype) is associated with decreased dose-adjusted trough concentrations of voriconazole as compared to CYP2C19 *1/*1.
3984 1445297704 CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizers and intermediate metabolizers phenotype) is associated with increased concentrations of voriconazole in healthy individuals as compared to CYP2C19 *1/*1 (assigned as normal metabolizers phenotype) .
3983 1444842618 CYP2C19 *1/*2 is associated with increased concentrations of voriconazole.
3982 1444842443 CYP2C19 *1/*1 (assigned as poor metabolizer phenotype) is associated with increased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *1/*2 + *2/*2.
3981 1444842336 CYP2C19 *1/*17 is associated with increased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *1/*2 + *2/*2.
3980 1444841988 CYP2C19 *1/*1 + *1/*17 is associated with decreased trough concentration of voriconazole in people with Hematologic Diseases as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2 + *3/*3.
3979 1444828207 CYP2C19 *2/*2 (assigned as poor metabolizer genotype phenotype) is associated with increased concentrations of voriconazole.
3978 1444828173 CYP2C19 *17 (assigned as ultrarapid metabolizer phenotype) is associated with decreased concentrations of voriconazole.
3977 1444828163 CYP2C19 *1/*17 is associated with decreased concentrations of voriconazole.
3976 1444828153 CYP2C19 *2/*2 (assigned as poor metabolizer genotype phenotype) is associated with increased concentrations of voriconazole.
3975 1444828143 CYP2C19 *17/*17 (assigned as ultrarapid metabolizer genotype phenotype) is associated with decreased concentrations of voriconazole.
3974 1444827994 CYP2C19 *2/*2 (assigned as poor metabolizer phenotype) is associated with increased concentrations of voriconazole as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .
3973 1444827966 CYP2C19 *1/*2 + *1/*3 (assigned as intermediate metabolizers phenotype) is associated with increased trough concentration of voriconazole in people with Hematologic Diseases and Infection as compared to CYP2C19 *1/*1 + *1/*17 (assigned as normal metabolizer phenotype) .
3972 1444827950 CYP2C19 *2/*2 + *3/*3 (assigned as poor metabolizer phenotype) is not associated with trough concentration of voriconazole in people with Hematologic Diseases and Infection as compared to CYP2C19 *1/*1 + *1/*17 + *1/*2 + *1/*3.
3971 1444827924 CYP2C19 *2/*2 is associated with decreased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *1/*1.
3970 1444713552 CYP2C19 *2/*2 + *1/*2 + *1/*3 (assigned as poor metabolizers and intermediate metabolizers phenotype) is associated with increased concentrations of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .
3969 1184753704 CYP2C19 *1/*2 (assigned as intermediate metabolizer phenotype) is associated with increased concentrations of voriconazole in men with Hepatitis C, Lymphoma and Shock, Septic.
3968 1184748535 CYP2C19 *2/*2 (assigned as poor metabolizer phenotype) is associated with increased dose-adjusted trough concentrations of voriconazole in children with Neoplasms as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .
3967 1184748512 CYP2C19 *1/*2 (assigned as intermediate metabolizer phenotype) is associated with increased dose-adjusted trough concentrations of voriconazole in children with Neoplasms as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .
3966 1184748497 CYP2C19 *1/*17 (assigned as ultrarapid metabolizer phenotype) is not associated with dose-adjusted trough concentrations of voriconazole in children with Neoplasms as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .
3965 1184748470 CYP2C19 *17/*17 (assigned as ultrarapid metabolizer phenotype) is associated with decreased dose-adjusted trough concentrations of voriconazole in children with Neoplasms as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .
3964 1184468739 CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .
3963 1183944026 CYP2C19 *1/*2 + *2/*2 are associated with decreased metabolism of voriconazole.
3962 1183944019 CYP2C19 *1/*1 + *1/*17 are associated with increased metabolism of voriconazole.
3961 1183849453 CYP2C19 *1/*17 + *17/*17 (assigned as ultrarapid metabolizer phenotype) is associated with increased metabolism of voriconazole in patients with decreased concentrations of voriconazole.
3960 1183849398 CYP2C19 *2/*2 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .
3959 1183849008 CYP2C19 *1/*17 (assigned as ultrarapid metabolizer phenotype) is associated with increased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *2/*2 (assigned as poor metabolizer phenotype) .
3958 1183848923 CYP2C19 *2/*2 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .
3957 1183848916 CYP2C19 *1/*17 (assigned as ultrarapid metabolizer phenotype) is associated with increased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .
3956 1183848503 CYP2C19 *2/*2 + *2/*3 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3.
3955 1183685442 CYP2C19 *1/*1 is associated with increased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *2/*2.
3954 982048012 CYP2C19 *2 + *3 are associated with increased trough concentration of voriconazole in children as compared to CYP2C19 *1 + *17.
3953 981565071 CYP2C19 *1/*17 is associated with increased metabolism of voriconazole in men with Granulomatous Disease, Chronic.
3952 1449732418 Genotypes *1/*1 + *1/*2 + *1/*3 (assigned as intermediate metabolizer and normal metabolizer phenotype) are not associated with metabolism of voriconazole in people with Mycoses.
3951 1449732409 Genotypes *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizers phenotype) are associated with decreased metabolism of voriconazole in people with Mycoses.
3950 1449146940 CYP2C19 ultrarapid metabolizer is associated with decreased trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 normal metabolizer.
3949 1449146934 CYP2C19 poor metabolizers and intermediate metabolizers are associated with increased trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 normal metabolizer.
3948 1448123512 CYP2C19 poor metabolizers and intermediate metabolizers are associated with increased trough concentration of voriconazole as compared to CYP2C19 normal metabolizers.
3947 1444827896 Genotypes *2/*2 + *2/*3 (assigned as poor metabolizer phenotype) is associated with increased trough concentration of voriconazole in people with Mycoses as compared to genotype *1/*1 (assigned as normal metabolizer phenotype) .
3946 1444827890 Genotypes *1/*2 + *1/*3 + *2/*17 (assigned as intermediate metabolizer phenotype) is associated with increased likelihood of Drug Toxicity when exposed to voriconazole as compared to CYP2C19 normal metabolizer.
3945 1444827885 Genotypes *1/*17 + *17/*17 (assigned as ultrarapid metabolizer phenotype) is associated with decreased concentrations of voriconazole as compared to genotype *1/*1 (assigned as normal metabolizer phenotype) .
3944 1444714180 Genotypes *1/*2 + *1/*3 (assigned as intermediate metabolizers phenotype) are associated with decreased metabolism of voriconazole in people with Mycoses as compared to genotype *1/*1 (assigned as normal metabolizer phenotype) .
3943 1444714094 Genotypes *1/*2 + *1/*3 + *2/*17 (assigned as intermediate metabolizers phenotype) are associated with increased concentrations of voriconazole as compared to genotype *1/*1 (assigned as normal metabolizers phenotype) .
3942 1183685147 CYP2C19 poor metabolizer genotype is associated with decreased metabolism of voriconazole in healthy individuals as compared to CYP2C19 normal metabolizer genotype.
3941 PA166104990 Annotation of DPWG Guideline for voriconazole and CYP2C19
3940 PA166161537 Annotation of CPIC Guideline for voriconazole and CYP2C19
2948 1450372533 CYP2C19 *2/*2 + *2/*3 is associated with decreased metabolism of voriconazole in people with as compared to CYP2C19 *1/*1.
2947 1450372517 CYP2C19 *1/*2 + *1/*3 + *2/*17 is associated with decreased metabolism of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.
2946 1449732457 CYP2C19 *2/*2 + *2/*3 + *1/*2 + *1/*3 + *2/*17 are associated with decreased metabolism of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.
2945 1449275114 CYP2C19 *2 + *3 is associated with increased concentrations of voriconazole in people with Kidney Transplantation as compared to CYP2C19 *1.
2944 1449161276 CYP2C19 *1/*17 is associated with decreased concentrations of voriconazole in people with Mycoses.
2943 1449146891 CYP2C19 *1/*2 is associated with increased concentrations of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1 + *1/*17.
2942 1448820856 CYP2C19 *1/*1 is associated with increased metabolism of voriconazole in people with Kidney Transplantation as compared to CYP2C19 *1/*2 + *1/*3 + *2/*17.
2941 1448616465 CYP2C19 *2 + *3 are associated with increased exposure to voriconazole in healthy individuals as compared to CYP2C19 *1 + *17.
2940 1448616451 CYP2C19 *1 + *17 are associated with decreased exposure to voriconazole in healthy individuals as compared to CYP2C19 *2 + *3.
2939 1448604948 CYP2C19 *17/*17 is associated with decreased concentrations of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1 + *1/*2 + *2/*17 + *2/*2.
2938 1448604929 CYP2C19 *1/*17 is associated with decreased concentrations of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1 + *1/*2 + *2/*17 + *2/*2.
临床病史
id类型评论
842 Update Added DPWG guideline.
841 Update CA score added as part of scoring system release. LOE assigned following curator review.
840 Update Since there are some no association studies, included sentence about this in the text.
839 Update Limited phenotype to PK and re-wrote to be on alleles not diplotypes. Added CPIC guideline as reason for level 1A.
838 Update Added PMID 29607533

最新招商产品更多>>

网站地图 - 网站开发 - 网站简介 - 会员服务 - 法律声明 - 联系我们 - 药品招商频道 - 药品信息排行 - 2018年版国家基本药物目录 - 意见反馈
免责声明：以上所展示的信息由企业自行提供，内容的真实性、准确性和合法性由发布企业负责，医药网对此不承担任何责任。
相关链接：医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究　　客服热线：0575-83552251 / 13754370441  QQ客服：药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证：浙B2-20220931　互联网药品信息服务资格证书编号：(浙)-经营性2023-0215　浙公网安备:330683240604819103159
　医药代理商群１：药药网药品采购交流医药代理商群２：药药网药品采购交流2医药代理商群３：药药网药品采购交流3